| Prev Close: | 7.51 |
|---|---|
| Open: | 7.82 |
| Bid: | 7.61 x 400 |
| Ask: | 7.68 x 900 |
| 1y Target Est: | 8.86 |
| Beta: | -0.86 |
| Next Earnings Date: | 7-Aug-13 |
| Day's Range: | 7.50 - 7.83 |
|---|---|
| 52wk Range: | 6.95 - 13.50 |
| Volume: | 7,069,181 |
| Avg Vol (3m): | 5,526,370 |
| Market Cap: | 1.66B |
| P/E (ttm): | N/A |
| EPS (ttm): | -0.37 |
| Div & Yield: | N/A (N/A) |
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Arena Pharmaceuticals CEO Presents at Wells Fargo Health Care Conference (Transcript)at Seeking Alpha(Wed 6:33PM EDT)
- Obesity Sector Gets New Shoesat Seeking Alpha(Wed 5:01PM EDT)
- It's Official: Obesity Is a Diseaseat Motley Fool(Wed 2:41PM EDT)
- AMA's Obesity-As-Disease Vote Should Boost Diet Drugsat Forbes(Wed 11:29AM EDT)
- 2 Biotech Approval Outcomes That Might Affect Youat Motley Fool(Wed 9:59AM EDT)
- Weight loss drug makers rise after AMA calls obesity a diseaseat theflyonthewall.com(Wed 9:49AM EDT)
- [video] Cramer's Mad Dash: Arena Pharma's Weighty Playat CNBC(Wed 9:23AM EDT)
- American Medical Association Decision Can Boost Arena, Vivus, And Orexigenat Seeking Alpha(Wed 12:22AM EDT)
- A.M.A. Recognizes Obesity as a Diseaseat New York Times(Tue, Jun 18)
- Consumer Reports Says "Exercise" Rather Than Take This Drugat Motley Fool(Mon, Jun 17)
- What Investors Need To Know About The Efficacy Of Belviqat Seeking Alpha(Mon, Jun 17)
- The Top 5 Diseases Caused by Obesityat Motley Fool(Sun, Jun 16)
- ARENA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a VEDGAR Online(Fri, Jun 14)
- BELVIQ® (lorcaserin HCl) CIV Data to be Presented at ENDO 2013PR Newswire(Fri, Jun 14)
- Arena Pharmaceuticals to Present at the 2013 Wells Fargo Securities Healthcare ConferencePR Newswire(Fri, Jun 14)
Press Releases
- BELVIQ® (lorcaserin HCl) CIV Data to be Presented at ENDO 2013PR Newswire(Fri, Jun 14)
- Arena Pharmaceuticals to Present at the 2013 Wells Fargo Securities Healthcare ConferencePR Newswire(Fri, Jun 14)
- Arena Pharmaceuticals Reports on Launch of BELVIQ® (lorcaserin HCl) CIV for Chronic Weight Management in Adults who are Overweight with a Comorbidity or ObesePR Newswire(Fri, Jun 7)
Reports
- ARNA: Due Diligence Review: Forensic Earnings and ValuationNew Constructs, LLC(Jun 19)
- ValuEngine Industry Report for Medical-biomed/geneticsValuEngine, Inc.(Jun 19)
- ARNA PHARMACEUTICALS INC (ARNA) - REPORT FOR ACTIVE TRADERSPechala's Reports(Jun 17)